- Roche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO)
- CHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition
- Roche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection
- Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis
- Roche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratories
- Roche launches new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma
- Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
- Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization
- European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer
- Five-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained the ability to sit, stand or walk
More ▼
Key statistics
As of last trade Roche Holding AG (RHO6:STU) traded at 32.16, -10.46% below its 52-week high of 35.92, set on Jul 25, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 32.16 |
---|---|
High | 32.16 |
Low | 32.16 |
Bid | 31.70 |
Offer | 32.37 |
Previous close | 32.07 |
Average volume | 0.22 |
---|---|
Shares outstanding | 6.47bn |
Free float | 328.26m |
P/E (TTM) | 17.41 |
Market cap | 225.80bn USD |
EPS (TTM) | 1.98 USD |
Annual div (ADY) | 1.24 EUR |
---|---|
Annual div yield (ADY) | 3.86% |
Div ex-date | Mar 14 2024 |
Div pay-date | May 03 2024 |
Data delayed at least 15 minutes, as of Jul 02 2024.
More ▼